Interestingly, all inhibitors significantly reduced endothelial sprouting and migration at a concentration of 100 μM, but not at 10 μM, further emphasizing the S1P-S1PR3 axis as a potential target for antiangiogenic therapies in S1P-secreting cancers. This evidence concerns the gene S1PR3 and cancer.